Together, we can help shape what’s next. Reach out to start the conversation.

General Contact
Message Us
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
General Contact
Message Us
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Scientific Updates

Discover the data behind our work

Upacicalcet is an investigational product candidate in the United States and has not been approved by the U.S. Food and Drug Administration (FDA). The content presented on this webpage is scientific in nature and is intended for US Healthcare Professionals.

May 22, 2026

Pathalys Participates in National Kidney Foundation (NKF) Spring Clinical Meeting 2026, New Orleans

Dr. Bastian Dehmel presented new data on upacicalcet’s mechanism of action. The in vitro results showed that upacicalcet activates the calcium-sensing receptor at the highest calcium set point compared to other calcimimetics tested in this study.

A new path for patients with Chronic Kidney Disease

Pathalys Pharma, Inc.
4000 Center at North Hills Street
Suite 470
Raleigh, NC 27609
Company
HomeDiscover PathalysAbout SHPTThe ScienceSpotlight
Policies
Terms of UsePrivacy Policy
Social
LinkedIn